Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab

BACKGROUND: The standard treatment for patients with unresectable locally advanced (LA) non‐small cell lung cancer (NSCLC) is chemoradiotherapy (CRT). Consolidation therapy with durvalumab after CRT demonstrated survival benefits and was approved in Japan in July 2018. The use of immune checkpoint i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Thorac Cancer
Hlavní autoři: Fukui, Tomoya, Hosotani, Shinji, Soda, Itaru, Ozawa, Takahiro, Kusuhara, Seiichiro, Kakegawa, Mikiko I., Kasajima, Masashi, Hiyoshi, Yasuhiro, Igawa, Satoshi, Yokoba, Masanori, Mitsufuji, Hisashi, Kubota, Masaru, Katagiri, Masato, Sasaki, Jiichiro, Ishiyama, Hiromichi, Naoki, Katsuhiko
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons Australia, Ltd 2020
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7113036/
https://ncbi.nlm.nih.gov/pubmed/32057187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13357
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky